Core Viewpoint - Fudan Zhangjiang (01349) experienced a nearly 3% decline in stock price following the announcement of its mid-year results for 2025, reflecting a decrease in revenue and profit [1] Financial Performance - The company reported revenue of approximately 390 million yuan, representing a year-on-year decrease of 4.42% [1] - Shareholder profit attributable to the company was 5.715 million yuan, a significant year-on-year decline of 91.89% [1] - Earnings per share were reported at 0.0055 yuan [1] Reasons for Profit Decline - The decline in profit was primarily attributed to an increase in research and development expenses compared to the same period last year [1] - The previous year's results included compensation and penalties related to the termination of cooperation with the promotional service provider, Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. [1]

Group 1 - Fudan Zhangjiang reported a revenue of 390 million yuan for the first half of 2025, a year-on-year decrease of 4.42%, and a net profit attributable to shareholders of 5.71 million yuan, down 91.89% year-on-year [1] - The company maintained a high R&D investment of 178 million yuan, which represents 45.63% of its revenue, an increase of 7.57% year-on-year [1] - The company is a leader in photodynamic therapy, with ongoing research expanding indications for its products, including treatments for cervical diseases and acne, which have completed Phase II clinical trials [1] Group 2 - The ADC technology platform is accelerating clinical trials, with ongoing Phase III trials for the anti-Trop2 antibody conjugate SN38 for triple-negative breast cancer and other tumor types [2] - Fudan Zhangjiang's production base in Taizhou is capable of large-scale commercial production for the F0024 project, supporting the ongoing Phase III clinical trial [2] - The company has completed technology transfer for the F0034 project, which is also preparing for Phase III clinical trial sample production [2] Group 3 - Due to not winning the bid for the tenth batch of national procurement, Fudan Zhangjiang has implemented a gradual price reduction for the product Libao Duo starting May 1, 2025, which may impact short-term revenue [3] - Despite short-term performance fluctuations, the company remains committed to innovation and R&D in photodynamic and ADC technology, aiming to drive long-term value [3] - As the pipeline gradually moves towards commercialization, Fudan Zhangjiang is expected to strengthen its position in the innovative drug sector [3]

公告称，利润下滑主要因为本报告期研发费用较上年同期有所增长，及上年同期与里葆多®推广服务商 辉正(上海)医药科技有限公司终止合作后公司确认了相应的补偿款及违约金。 智通财经APP讯，复旦张江(01349)公布2025年中期业绩，收入约3.9亿元，同比减少4.42%;公司股东应 占溢利571.5万元，同比减少91.89%;每股盈利0.0055元。 ...

报告期内利润总额及归属于上市公司股东的净利润等相关财务指标下降明显主要因为报告期研发费用较 上年同期有所增长，及上年同期与里葆多®推广服务商上海辉正终止合作后公司确认相应补偿款及违约 金。 智通财经APP讯，复旦张江(688505.SH)披露2025年半年度报告，报告期公司实现营收3.9亿元，同比下 降4.42%;归属于上市公司股东的净利润572万元，同比下降91.89%;扣非净利润亏损949万元，同比由盈 转亏;基本每股收益0.01元。 ...

Core Viewpoint - Fudan Zhangjiang reported a significant decline in both revenue and net profit for the first half of the year, primarily due to increased R&D expenses and the absence of compensation from a previous partnership [1] Financial Performance - The company achieved a revenue of 390 million yuan, representing a year-on-year decrease of 4.42% [1] - The net profit attributable to shareholders was 5.71 million yuan, down 91.89% from 70.47 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.01 yuan [1] Factors Influencing Performance - The decline in financial metrics was mainly attributed to an increase in R&D expenses compared to the previous year [1] - The previous year's financials included compensation and penalties from the termination of a partnership with Shanghai Huizheng, which did not recur in the current reporting period [1]